Real-world data on treatment outcomes in EGFR-mutant non-small-cell lung cancer patients receiving osimertinib in second or further lines.

doi:10.2217/fon-2021-0356

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Real-world data on treatment outcomes in EGFR-mutant non-small-cell lung cancer patients receiving osimertinib in second or further lines.

Future oncology (London, England) - 1 Jul 2021

Dal Maso Alessandro, Lorenzi Martina, Ferro Alessandra, Pilotto Sara, Cecere Fabiana, Follador Alessandro, Polo Valentina, Del Conte Alessandro, Sartori Giulia, Giavarra Marco, Scattolin Daniela, Indraccolo Stefano, Frega Stefano, De Maglio Giovanna, Menis Jessica, Bonanno Laura, Calabrese Fiorella, Guarneri Valentina, Conte PierFranco, Pasello Giulia

Abstract excerpt

Aims: This study describes real-world outcomes of pretreated EGFR T790M-positive (T790M+) advanced non-small-cell lung cancer patients progressing after first- or second-generation tyrosine kinase inhibitors and receiving osimertinib, compared with T790M-negative (T790M-) patients. We have also described progression patterns and treatment sequences. Patients & methods: This is a retrospective multicenter Italian...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acrylamides

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Aniline Compounds

Share to Carcinoma, Non-Small-Cell Lung

Share to ErbB Receptors

Share to Follow-Up Studies

Share to Kaplan-Meier Estimate

Share to Progression-Free Survival

Share to Protein Kinase Inhibitors

Source

Open in PubMed

Identifiers

PMID: 33988036
DOI: 10.2217/fon-2021-0356

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Real-world data on treatment outcomes in EGFR-mutant non-small-cell lung cancer patients receiving osimertinib in second or further lines.PMID 33988036Read ↗

A real-world study of second or later-line osimertinib in patients with EGFR T790M-positive NSCLC: the final ASTRIS data.Semantic proximity Read ↗

Comparing survival and treatment response of patients with acquired T790M mutation second-line osimertinib versus sequential treatment of chemotherapy followed by osimertinib: A real-world study.Semantic proximity Read ↗

Different Survival Benefit of Osimertinib in Different Sequences: A Real‐World Outcome of Osimertinib Treatment in Pretreated T790M-Positive Advanced NSCLC in TaiwanSemantic proximity Read ↗

Favorable survival outcomes in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer sequentially treated with a tyrosine kinase inhibitor and osimertinib in a real-world setting.Semantic proximity Read ↗

The Real-Life Efficacy And Safety of Osimertinib In Pretreated Advanced Non-Small Cell Lung Cancer Patients With T790M Mutation: A Turkish Oncology Group StudySemantic proximity Read ↗

Empirical Osimertinib as a Second-Line Treatment Is a Viable Option Following First- and Second-Generation TKI Therapy With Unknown EGFR Status in Treated Non-Small Cell Lung Cancer: A Retrospective Study.Semantic proximity Read ↗

Efficacy and safety of first-line osimertinib treatment and postprogression patterns of care in patients with epidermal growth factor receptor activating mutation-positive advanced non-small cell lung cancer (Reiwa study): study protocol of a multicentre, real-world observational study.Semantic proximity Read ↗

Real-world osimertinib for EGFR mutation-positive non-small-cell lung cancer with acquired T790M mutation.Semantic proximity Read ↗

Treatment Patterns and Clinical Outcomes in Patients With EGFR-Mutated Non-Small-Cell Lung Cancer After Progression on Osimertinib.Semantic proximity Read ↗

The real-life efficacy and safety of osimertinib in pretreated advanced non-small cell lung cancer patients with T790M mutation: a Turkish Oncology Group Study.Semantic proximity Read ↗

Osimertinib in Advanced EGFR-T790M Mutation-positive Non-small Cell Lung Cancer Patients Treated Within the Special Use Medication Program in Spain. OSIREX-spanish Lung Cancer GroupSemantic proximity Read ↗

Real-world efficacy of osimertinib in previously EGFR-TKI treated NSCLC patients without identification of T790M mutation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.